

ASX MEDIA RELEASE

4 April 2022

Appointment of Chief Financial Officer

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the appointment of David Green as Chief Financial Officer (CFO). Outgoing CFO Robert Vickery will continue to serve as Company Secretary.

Mr Green joins Clarity with over 25 years’ experience in senior finance roles in a range of Australian Securities Exchange (ASX) listed and unlisted companies including Ernst & Young, Sigma Pharmaceuticals, Chiquita Brands (now Costa Exchange) and Alchemia Limited. Most recently he was CFO of Ellume Ltd, a Brisbane based diagnostic manufacturer.

Outgoing Chief Financial Officer Robert Vickery said, “Due to Clarity’s rapid and continued growth and my other professional commitments I have decided to reduce the scope of my role at the Company. I have been working closely with David over the past 3 months to transition the role. His appointment is an excellent addition for Clarity and greatly strengthens our corporate team. Clarity is a wonderful company built on strong locally developed science. I am very pleased to be able to continue to serve the company and its shareholders and to work with Alan, David and the rest of the fantastic team at Clarity.”

Clarity’s Executive Chairman, Dr Alan Taylor commented, “I am very pleased to welcome David to our team. He brings a wealth of highly relevant experience to Clarity as we continue to develop and grow towards our ultimate goal of better treating children and adults with cancer. Robert was a crucial member of our team during the listing process as we became the largest ever biotechnology Initial Public Offering (IPO) on the ASX, especially in his important role of further developing a strong culture of corporate governance. We thank him for his contribution to date and we are very pleased that he will continue to contribute to the company. His experience, including as CFO of Viralytics through its acquisition by Merck & Co. Inc., will be invaluable as Clarity charts its future growth.”

This announcement has been authorised for release by the Executive Chairman.

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairman

ataylor@claritypharm.com

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com